Some of the names on the move ahead of the open.» Read More
U.S. stocks were lower this morning, after Wednesday's severe slide sent Wall Street to its lowest level since late September.
Biotech CEOs say that drug pricing needs to be balanced enough to support research and development.
Biotech stocks endured a rough Monday, and struggles may continue throughout the year for the high-growth sector, one trader said.
Several factors are being overlooked when discussing drug pricing in the U.S., three pharma CEOs say.
Health care is leading the market lower today. The FMHR traders discuss their best strategy in looking at this group of stocks.
Jim Cramer helps investors manage market anxiety with his tips to making money in a world of fear.
Adding large-cap names to your portfolio.
Prominent investor Martin Sass is taking a cautious investment stance after being bullish for most of the market run since 2009.
*Sanofi and Mannkind terminate deal for Afrezza. LONDON, Jan 5- French drugmaker Sanofi is to stop selling an inhalable insulin developed by Mannkind, following disappointing sales of the product since its launch in February 2015. Rights to Afrezza will revert to Mannkind from Sanofi in the next 90 to 180 days and Mannkind said it was reviewing strategic options...
Stocks suffered Monday to start 2016, but "Fast Money" traders saw opportunities in the slide.
Jim Cramer prepares investors with his shopping list of stocks to avoid and buy amid the worldwide sell-off.
There's a case to be made for the Dogs of the Dow, even as stocks start 2016 down. They offer yields that can pay off a mortgage.
A slower-growing China, diverging central bank actions and a cutthroat battle among global energy producers were themes.
2015 was a record year for mergers. Here's what the research reveals about how 2016 will compare, says Matt Porzio.
*Pep Boys up after board finds Icahn's proposal superior. Dec 29- Wall Street rose sharply on Tuesday, elevating the S&P 500 to a modest gain for the year as Amazon and Apple led tech stocks higher. Amazon climbed 2.78 percent and closed at a record high of $693.97.
Here are the top 10 business stories of the year, in descending order. NBCNews reports.
Prosecutors said the trades enabled SAC Capital to make $275 million, making it the most lucrative insider trading case ever charged in the United States. The $10 million class action accord, which requires court approval, follows earlier deals with U.S. authorities in which SAC Capital agreed to pay $1.8 billion and plead guilty following investigations...
Apple’s decision to give shareholders a greater say in boardroom appointments is a significant victory, campaigners have said. The FT reports.
NEW YORK, Dec 23- A new class of blood thinners that competes with widely used warfarin should get a boost next year when an "antidote" that can reverse the medications' effects in an emergency is expected to enter the market, according to top U.S. heart doctors and investors. Xarelto, from Bayer AG and Johnson& Johnson, and Eliquis, sold by Bristol-Myers Squibb and...
2015 has been a record year for mergers and acquisitions (M&A). CNBC looks back at the 10 biggest deals of the year and who advised on them.